Nitin Y. Bhatt

TL;DR: The INBUILD trial suggests that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis.

TL;DR: At the extremes of age and height, a large number of spirometry test results will be interpreted as showing an obstructive defect if a 70% fixed ratio method is used for interpretation compared with the LLN derived from the Hankinson data set.

TL;DR: Functional and epigenomic data indicate that the risk variants near SOX17 alter gene regulation via an enhancer active in endothelial cells that determined Pulmonary arterial hypertension risk variants determined haplotype-specific enhancer activity, and CRISPR-mediated inhibition of the enhancer reduced SoX17 expression.

TL;DR: In this paper, the authors defined acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILDs.

TL;DR: Results suggest that monocyte survival factors may suppress DNA fragmentation, caspase-9, and caspases-3 activation in a PI 3-kinase-dependent manner, perhaps through the activation of Akt.